ALDH1A3 and colorectal carcinoma: Numerous studies point to inhibition of DCLK1 (100), down-regulation of MUC1-C (101), down-regulation of ALDH1B1 (102), down-regulation of KDM2B (103), down-regulation of NEAT1 (83), polymethoxylated flavones (104), resveratrol (105), ALDH1A3 inhibitor (88), 5-fluorouracil (106), grape pomace (107), montelukast (108), celecoxib targeted therapy (109), puerarin (110), can both down-regulate the expression of ALDH1 in CRC and reduce cell migration, invasion, and chemotherapy resistance.